SGNLVA-002: Single arm, open-label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer
Dokumenttyp:
Meeting Abstract
Autor(en):
Cortes, J.; Diab, S.; Basho, R. K.; Oliveira, M.; Pluard, T.; Alemany, C.; Brown-Glaberman, U.; Meisel, J.; Boni, V.; Sinha, R.; Garcia Estevez, L.; Ettl, J.; Kuemmel, S.; Manso Sanchez, L. M.; Moon, Y. W.; Villanueva Vazquez, R.; Wuerstlein, R.; Wang, Y.; Wang, Z.; Han, H.